Howe & Rusling’s 2seventy bio TSVT Stock Holding History

Howe & Rusling’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17	Closed	–	–	986
2022 Q3	$0	Buy	17 +7	+70%	+$104	﹤0.01%	1190
2022 Q2	$0	Hold	10	–	–	﹤0.01%	1161
2022 Q1	$0	Sell	10 -2	-17%	-$34	﹤0.01%	1082
2021 Q4	$0	Buy	+12	New	+$374	﹤0.01%	1069

Other funds holding TSVT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Howe & Rusling's TSVT Position: Q4 2022 in Review

Howe & Rusling sold out of 2seventy bio (TSVT) in Q4 2022, closing a stake of 17 shares.

Howe & Rusling first reported a position in TSVT in Q4 2021 and held it in 4 quarters. The position peaked at $0 in Q3 2022. 141 funds tracked by Wall St. Rank hold TSVT as of Q4 2022.

Howe & Rusling reported no remaining 2seventy bio position as of Q4 2022 after selling out during the quarter.
Howe & Rusling sold 17 2seventy bio shares in Q4 2022.
Howe & Rusling first reported a position in 2seventy bio in Q4 2021 and held it in 4 quarters.
Howe & Rusling's 2seventy bio position peaked at $0 in Q3 2022.
141 funds tracked by Wall St. Rank held 2seventy bio as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.